TET2 and myelodysplastic syndrome: The authors found that SIRT1 levels, and hence TET2 activity, were decreased in aberrant HSPCs in myelodysplastic syndrome (MDS), whereas overexpression of SIRT1 or its activation by agonist SRT1720 resulted in reduced myelodysplastic HSC survival.